INCELL has successfully completed innovative work establishing several unique human epithelial cell lines of normal small intestine. These cells have been partially characterized and preliminary transport studies suggest that they have characteristics more similar to the small intestine than the Caco-2 cell model. In Phase II, further characterization of these cells will be done. We will examine site-specific differences between the cell lines and determine if passage number or differentiation state effect cellular function. Reproducibility studies of the transport systems will lead to development of a commercial product that can be shipped in a ready to use format. The proposed transport models will be designed to be superior to the current model and serve as the new gold standard for intestinal cell line testing. The addition of these unique transport models, cell cultures and RNA and protein extracts from these cell lines will expand INCELL's products and services capabilities and allow INCELL to capture the majority share of the current markets. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
2R44DK059785-02A1
Application #
6646290
Study Section
Special Emphasis Panel (ZRG1-SSS-3 (10))
Program Officer
Densmore, Christine L
Project Start
2001-08-15
Project End
2004-11-30
Budget Start
2003-06-15
Budget End
2004-11-30
Support Year
2
Fiscal Year
2003
Total Cost
$375,469
Indirect Cost
Name
Incell Corporation, LLC
Department
Type
DUNS #
965420953
City
San Antonio
State
TX
Country
United States
Zip Code
78249